Brian Feth and Jonathan Grinstein go behind the headlines to discuss the impact of a Republican administration on Federal ...

The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

Friday Headlines: 38 y/o Brent Maloy is the first person in SC to undergo gene therapy treatment after living with Hemophilia ...

Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen. Thank you for standing by.